Company Encyclopedia
View More
name
DUO RUI PHARMA
301075.SZ
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, intermediates, and raw materials in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as sodium acetate ringer's injection; and agent products, such as amoxicillin sodium and clavulanate potassium for injection, etc. The company was founded in 2005 and is headquartered in Tibet, China.
3.099 T
301075.SZMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking202/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-18.97%E
    • Profit Margin-70.76%E
    • Gross Margin-5.31%E
  • Growth ScoreE
    • Revenue YoY-38.62%E
    • Net Profit YoY-614.51%E
    • Total Assets YoY35.27%A
    • Net Assets YoY-16.38%E
  • Cash ScoreE
    • Cash Flow Margin-141.33%D
    • OCF YoY-38.62%E
  • Operating ScoreE
    • Turnover0.14E
  • Debt ScoreD
    • Gearing Ratio55.73%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    DUO RUI PHARMA released its performance for the first three quarters, with a net loss attributable to the parent company of 79.7277 million yuan

    According to the Zhitong Finance APP, DUO RUI PHARMA released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 137 million yuan, a year-on-year decrease of 43.07%. The net loss attributable to shareholders of the listed company was 79.7277 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 84.9485 million yuan. The basic loss per share was 1.0064 yuan

    Zhitong·
    SZ
    301075
    -1.77%
    Zhitong·
    SZ
    301075
    -1.77%

    DUO RUI PHARMA: Expected to be unable to resume trading on October 9, will continue to be suspended for no more than 3 trading days

    DUO RUI PHARMA announced that the company's stock will be suspended from trading starting September 29, 2025, with the original plan for the suspension not to exceed 2 trading days. Due to the controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and the actual controller, Deng Yong, planning a change in the company's control, the overall plan is still under negotiation and a formal agreement has not yet been signed. The company expects that it will not be able to resume trading on October 9, 2025, and will continue to be suspended for no more than 3 trading days

    Zhitong·
    SZ
    301075
    -1.77%
    Zhitong·
    SZ
    301075
    -1.77%

    DUO RUI PHARMA: The company's control may change, and trading will be suspended starting September 29

    According to the Zhitong Finance APP, DUO RUI PHARMA announced that its controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd. (referred to as "Tibet Jiakang"), and the actual controller, Mr. Deng Yong, are planning matters related to the change of control of the company, which may lead to a change in the company's controlling shareholder and actual controller. The company's stock will be suspended from trading starting from the morning of September 29, 2025 (Monday), and the suspension is expected to last no more than 2 trading days

    Zhitong·
    SZ
    301075
    -1.77%
    Zhitong·
    SZ
    301075
    -1.77%

    DUO RUI PHARMA and others established a health technology company in Beijing

    According to the Qichacha APP, recently, Beijing DUO RUI YONG HE Health Technology Co., Ltd. was established, with Gao Jiazai as the legal representative and a registered capital of 10 million yuan. The business scope includes: health consulting services; remote health management services; sales of health food; acquisition of Chinese herbal medicine; retail of edible agricultural products, etc. Qichacha's equity penetration shows that the company is jointly held by Wuhan Jirui Health Industry Investment Co., Ltd., a subsidiary of DUO RUI PHARMA, and Beijing Yonghe Lize Hotel Management Co., Ltd

    Zhitong·
    SZ
    301075
    -1.77%
    Zhitong·
    SZ
    301075
    -1.77%

    DUO RUI PHARMA has obtained the drug registration certificate for injectable cefazolin sodium

    DUO RUI PHARMA's wholly-owned subsidiary, Hubei DUO RUI Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable cefazolin sodium issued by the National Medical Products Administration. This medication is suitable for various infections, including lower respiratory tract infections, urinary tract infections, and abdominal cavity infections

    Zhitong·
    SZ
    301075
    -1.77%
    Zhitong·
    SZ
    301075
    -1.77%
    © 2025 Longbridge｜Disclaimer